Virpax Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.11.24	Why Is Virpax Pharmaceuticals Stock Gaining On Friday? (Benzinga)
10.07.24	Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why? (Benzinga)
08.07.24	What's Going With Penny Stock Virpax Pharmaceuticals On Monday? (Benzinga)
27.02.24	Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price (Businesswire)
27.02.24	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. (Businesswire)
07.02.24	Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research (Businesswire)
29.12.23	Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting (Businesswire)
17.11.23	Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing (Businesswire)
17.11.23	Virpax Pharmaceuticals Announces Leadership Transition (Businesswire)
15.11.23	Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments (Businesswire)
12.10.23	Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research (Businesswire)
02.10.23	Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals (Businesswire)
27.09.23	Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies (Businesswire)
26.09.23	Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI (Businesswire)
18.09.23	Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals (Businesswire)
05.09.23	Virpax Pharmaceuticals Updates on Litigation (Businesswire)
14.08.23	Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments (Businesswire)
13.07.23	Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery (Businesswire)
21.06.23	Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council (Businesswire)
20.06.23	Virpax Pharmaceuticals Announces CFO Transition (Businesswire)
13.06.23	Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (Businesswire)
10.05.23	Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar (Businesswire)
04.05.23	Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023 (Businesswire)
27.04.23	Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™ (Businesswire)
05.04.23	Virpax Reports on Progress of Envelta™ (Businesswire)
28.03.23	Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors (Businesswire)
22.03.23	Virpax Pharmaceuticals Reports 2022 Year-End Results (Businesswire)
13.02.23	Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET) (Businesswire)
31.01.23	Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China (Businesswire)
18.01.23	Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™ (Businesswire)
10.01.23	Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts (Businesswire)
04.01.23	Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324) (Businesswire)
14.12.22	Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324) (Businesswire)
09.11.22	Virpax Pharmaceuticals Reports 2022 Third Quarter Results (Businesswire)
24.08.22	Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain (Businesswire)
15.08.22	Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments (Businesswire)
05.07.22	Virpax Pursues OTC Medical Device Pathway for AnQlar™ (Businesswire)
27.06.22	Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis (Businesswire)
19.05.22	Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (Businesswire)
16.05.22	Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments (Businesswire)
05.05.22	Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research (Businesswire)
26.04.22	Virpax Successfully Completes Initial Preclinical Studies for VRP324 (Businesswire)
31.03.22	Virpax Pharmaceuticals Reports 2021 Year-End Results (Businesswire)
22.03.22	Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™ (Businesswire)
15.03.22	Virpax Pharmaceuticals erweitert seine Entwicklungs- und Vermarktungsrechte an AnQlar™ mit weltweiter Lizenzvereinbarung (Businesswire)
15.03.22	Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement (Businesswire)
15.02.22	News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19 (Businesswire)
10.02.22	Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain (Businesswire)
18.01.22	Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™ (Businesswire)
04.01.22	Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Virpax Pharmaceuticals Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten